Biopharma
Biopharma Layoff Tracker 2024: Anokion, GlycoMimetics, Relay and More Cut Staff
Biopharma, Layoffs, 2024, Anokion, GlycoMimetics, Relay, Restructuring, Job Cuts, Industry Trends
Canaan Partners Raises Additional $100M for Biotech Investments, Adds Pfizer Vet Uwe Schoenbeck
Canaan Partners, Biotech investments, Venture capital, Pfizer, Uwe Schoenbeck, Biopharma, Healthcare, Venture partner
Biopharma Layoff Tracker 2024: Industry-Wide Job Cuts Continue
Biopharma, Layoffs, Job Cuts, Industry Tracker, 2024
Biopharma Layoff Tracker 2024: Merck, Rapt, Aslan and More Cut Staff
Biopharma, Layoffs, Merck, Rapt, Aslan, Pharmaceutical Industry, Job Cuts, Restructuring
Layoffs Persist, GLP-1s Launch for Weight Loss in China
GLP-1, weight loss, China, Novo Nordisk, Eli Lilly, layoffs, biopharma industry, semaglutide, tirzepatide, obesity, diabetes
Pfizer Faces Key R&D Challenges as Chief Scientific Officer Mikael Dolsten Departs
Pfizer, Mikael Dolsten, Chief Scientific Officer, R&D Challenges, Biopharma Industry
Biopharma Layoff Tracker 2024: CureVac, Takeda, Aerovate and More Cut Staff
Biopharma, Layoffs, 2024, CureVac, Takeda, Aerovate, Job Cuts, Industry Trends
Amylyx Acquires GLP-1 Receptor Antagonist for $35M to Fill Pipeline Gap
Amylyx Pharmaceuticals, Relyvrio, GLP-1 receptor antagonist, Eiger Biopharma, pipeline expansion, ALS, Wolfram syndrome
Day One Biopharma Expands Pipeline with $55 Million Acquisition of MabCare’s Phase 1-Ready ADC
Day One Biopharma, MabCare, Antibody Drug Conjugate (ADC), PTK7, Cancer Treatment, Biotech Acquisition, Pipeline Expansion
Western In-Licensing Deals with Chinese Companies: Focus on Disease Areas and Drug Types
, In-licensing deals, Chinese pharmaceutical companies, Western pharmaceutical companies, Disease areas, Drug types, Cross-border partnerships, Biopharma, Licensing trends,